Exploring Emerging Therapies in the Retinal Vascular Disease Pipeline

The final segment highlights the rapidly evolving pipeline of retinal vascular disease therapies and offers closing reflections from the panelists. The discussion emphasizes the promise of next-generation agents, including sustained-release implants, tyrosine kinase inhibitors (TKIs), and gene therapies. TKIs are viewed as the most imminent advancement, potentially shifting care toward maintenance-based approaches by providing continuous VEGF inhibition with reduced injection frequency. Gene therapy is described as the “holy grail” for long-term disease control, with the potential to turn the eye into a self-sustaining biologic factory. The experts also acknowledge logistical and reimbursement challenges that may shape adoption. Despite uncertainties, optimism prevails: the field is on the brink of a paradigm shift offering unprecedented durability and convenience. The program concludes with reflections on clinical progress, enthusiasm for innovation, and a shared commitment to improving patient outcomes through advancing science and technology.